(Q37257292)

19 August 2017

1 reference

title

Targeted manipulation of apoptosis in cancer treatment (English)

1 reference

19 August 2017

0 references

Justin A Call

1

1 reference

19 August 2017

S Gail Eckhardt

series ordinal

2

1 reference

19 August 2017

D Ross Camidge

series ordinal

3

1 reference

19 August 2017

publication date

27 August 2008

1 reference

Lancet Oncology Commission

19 August 2017

published in

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1002-1011

1 reference

The role of apoptosis in cancer development and treatment response

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

The Bcl-2 apoptotic switch in cancer development and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Portrait of a killer: the mitochondrial apoptosome emerges from the shadows

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Intrinsic tumour suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Antisense therapy in malignant diseases: status quo and quo vadis?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Structural biology of the Bcl-2 family of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Investigations on gossypol: past and present developments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Discovery of a novel small molecule binding site of human survivin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

The proteasome: a worthwhile target for the treatment of solid tumours?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Regulation of survivin function by Hsp90

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Rational design of shepherdin, a novel anticancer agent.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

The promise of TRAIL--potential and risks of a novel anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Targeting death receptors in cancer with Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

TRAIL death receptors and cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970209-2

7 January 2021

10.1016/S1470-2045(08)70209-2

Identifiers

DOI

1 reference

19 August 2017

1 reference